Literature DB >> 8865961

Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991.

R Z Litten, J Allen, J Fertig.   

Abstract

Research on medications to treat alcohol problems has flourished in the last 5 years. Whereas before this time most projects focused on withdrawal agents, at least equal interest has now extended to drugs that may directly reduce urge to drink. The most promising medications in this regard are the opiate antagonists and acamprosate. Considerable attention has also been devoted to serotonergic agents. As aids to detoxification, pharmacologic agents that affect the multiple neural systems disrupted by acute alcohol withdrawal remain under active investigation. Significant progress is also being made in identifying medications to assist alcoholics suffering collateral psychopathology, especially depression and anxiety based disorders. Unfortunately, fewer gains have been realized in the development of medications to assist patients simultaneously dependent on both alcohol and illicit drugs. Also, research to develop amethystic agents remains in its very early stages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865961     DOI: 10.1111/j.1530-0277.1996.tb05264.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  17 in total

1.  Enhanced 5-HT(2A) receptor status in the hypothalamus and corpus striatum of ethanol-treated rats.

Authors:  K G Akash; K S Balarama; C S Paulose
Journal:  Cell Mol Neurobiol       Date:  2008-04-19       Impact factor: 5.046

Review 2.  Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date.

Authors:  Mary R Lee; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 3.  Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

Authors:  M I Wilde; A J Wagstaff
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

Authors:  Emmamuel O Akala; Pornruedee Wiriyacoonkasem; Gaofeng Pan
Journal:  Drug Dev Ind Pharm       Date:  2011-03-30       Impact factor: 3.225

Review 5.  Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism.

Authors:  C Gianoulakis
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

6.  Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article.

Authors:  Raye Z Litten; Daniel E Falk; Stephanie S O'Malley; Katie A Witkiewitz; Karl F Mann; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2017-05-23       Impact factor: 3.455

7.  Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles.

Authors:  Wusheng Yin; Emmanuel O Akala; Robert E Taylor
Journal:  Int J Pharm       Date:  2002-09-05       Impact factor: 5.875

8.  Enhanced 5-HT(2A) receptors in brain stem and ALDH activity in brain stem and liver: 5-HT(2A) regulation on ALDH in primary hepatocytes cultures in vitro.

Authors:  Akash K George; T R Anju; C S Paulose
Journal:  Neurochem Res       Date:  2009-03-14       Impact factor: 3.996

9.  Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.

Authors:  Lara A Ray; David W Oslin
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

Review 10.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.